- Home
- MBC vs ANAB Comparison
MBC vs ANAB Comparison
Compare MBC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBC | ANAB |
|---|---|---|
| Founded | 1954 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MBC | ANAB |
|---|---|---|
| Price | $8.59 | $58.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $15.00 | ★ $66.70 |
| AVG Volume (30 Days) | ★ 2.8M | 452.7K |
| Earning Date | 05-11-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,734,700,000.00 | $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.45 | $43.04 |
| P/E Ratio | $42.74 | ★ N/A |
| Revenue Growth | 1.27 | ★ 157.01 |
| 52 Week Low | $8.73 | $15.32 |
| 52 Week High | $14.23 | $63.47 |
Technical Indicators
Market Signals| Indicator | MBC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 21.69 | 59.89 |
| Support Level | N/A | $43.67 |
| Resistance Level | $13.56 | N/A |
| Average True Range (ATR) | 0.59 | 3.62 |
| MACD | -0.26 | 0.08 |
| Stochastic Oscillator | 11.47 | 55.05 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).